Number
Part Name
Part type
Part type
diagram
Short Description
Ozoralizumab
Basic part
Coding
Ozoralizumab is a next-generation TNFα antibody composed of two nanoparticles specifically targeting human TNFα and one nanoparticle directed towards human albumin.
V565
Basic part
Coding
Upon administration, the V565 capsules are gradually solubilized by the varying pH levels of gastric and intestinal fluids, facilitating the release of active V5-65 which subsequently binds to inflamed regions of the intestinal epithelium
p15A-Ozoralizumab
Composite part
Plasmid
The design of our experiment employs a comprehensive approach to treating the disease through a combination of therapeutic agents, including A-nanobody, a nanobody derived from Ozoralizumab
p15A-V565
Composite part
Plasmid
The design of our experiment employs a comprehensive approach to treating the disease through a combination of therapeutic agents, including A-nanobody, a nanobody derived from V565